Dodick D - Search Results

1

Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study.

Tepper SJ, Cady R, Dodick D, Freitag FG, Hutchinson SL, Twomey C, Kuhn TA. Tepper SJ, et al. Among authors: dodick d. Headache. 2006 Jan;46(1):115-24. doi: 10.1111/j.1526-4610.2006.00300.x. Headache. 2006. PMID: 16412159 Clinical Trial.

2

Diagnosis and treatment of migraine.

Cady R, Dodick DW. Cady R, et al. Mayo Clin Proc. 2002 Mar;77(3):255-61. doi: 10.4065/77.3.255. Mayo Clin Proc. 2002. PMID: 11888029 Review.

3

Almotriptan increases sustained pain-free outcomes in acute migraine: results from three controlled clinical trials.

Dodick DW. Dodick DW. Headache. 2002 Jan;42(1):21-7. doi: 10.1046/j.1526-4610.2002.02009.x. Headache. 2002. PMID: 12005271 Clinical Trial.

4

How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials.

Dahlöf CG, Dodick D, Dowson AJ, Pascual J. Dahlöf CG, et al. Among authors: dodick d. Headache. 2002 Feb;42(2):99-113. doi: 10.1046/j.1526-4610.2002.02025.x. Headache. 2002. PMID: 12005302 Review.

5

Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine.

Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, Loutfi H, Welch KM, Goadsby PJ, Hahn S, Hutchinson S, Matchar D, Silberstein S, Smith TR, Purdy RA, Saiers J; Triptan Cardiovascular Safety Expert Panel. Dodick D, et al. Headache. 2004 May;44(5):414-25. doi: 10.1111/j.1526-4610.2004.04078.x. Headache. 2004. PMID: 15147249 Review.

6

Triptan nonresponder studies: implications for clinical practice.

Dodick DW. Dodick DW. Headache. 2005 Feb;45(2):156-62. doi: 10.1111/j.1526-4610.2005.05031.x. Headache. 2005. PMID: 15705122

7

Duration of migraine is a predictor for response to botulinum toxin type A.

Eross EJ, Gladstone JP, Lewis S, Rogers R, Dodick DW. Eross EJ, et al. Headache. 2005 Apr;45(4):308-14. doi: 10.1111/j.1526-4610.2005.05067.x. Headache. 2005. PMID: 15836566 Clinical Trial.

8

Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.

Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD; BOTOX CDH Study Group. Dodick DW, et al. Headache. 2005 Apr;45(4):315-24. doi: 10.1111/j.1526-4610.2005.05068.x. Headache. 2005. PMID: 15836567 Clinical Trial.

9

Sinus headache: a neurology, otolaryngology, allergy, and primary care consensus on diagnosis and treatment.

Cady RK, Dodick DW, Levine HL, Schreiber CP, Eross EJ, Setzen M, Blumenthal HJ, Lumry WR, Berman GD, Durham PL. Cady RK, et al. Among authors: dodick dw. Mayo Clin Proc. 2005 Jul;80(7):908-16. doi: 10.4065/80.7.908. Mayo Clin Proc. 2005. PMID: 16007896 Review.

10

Removing barriers to appropriate migraine treatment: formulary limitations and triptan package size.

Silberstein SD, Dodick D, Kesslick J. Silberstein SD, et al. Among authors: dodick d. Headache. 2005 Oct;45(9):1250-4. doi: 10.1111/j.1526-4610.2005.00250.x. Headache. 2005. PMID: 16178957 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

574 results

Search Page

Filters